Forbion European Acquisition Corp

Forbion European Acquisition Corp. is a blank check company that was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination. The company was founded on August 9, 2021 and is headquartered in Wilmington, DE.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Forbion European Acquisition Corp. is a blank check company. It engages in the business of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. The company was founded by Hugo Alexander Slootweg in 2006 and is headquartered in Wilmington, DE.

Business combination transaction completed with Forbion European Acquisition Corp. Clinical stage biotechnology company with EG-70 lead program in pivotal clinical study targeting BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) $138M in gross proceeds from transaction to support advancement of EG-70 clinical program, which is currently enrolling patients, and continued pipeline expansion in additional therapeutic areas BOSTON and MONTREAL, Nov. 1, 2023 /PRNewswire/ - enGene Holdings Inc. ("enGene" or the "Company,") (NASDAQ: ENGN) today announced the completion of the previously announced business combination between enGene Inc., a clinical-stage genetic medicines company whose lead program is in a pivotal study for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), and Forbion European Acquisition Corp. ("FEAC," Nasdaq: FRBN), a special purpose acquisition company. The Company also announced a concurrent transaction financing.

enGene (Nasdaq: ENGN) Launched as Publicly Traded Genetic Medicines Company

In general, market sentiment around special purpose acquisition companies (SPACs) has dwindled considerably since 2020-2021. That said, certain SPAC companies continue to see outsized interest.

Why Is Forbion European Acquisition (FRBN) Stock Up 100% Today?

News for Forbion European Acquisition Corp Stock (FRBN)